Literature DB >> 22664962

Production of lentiviral vectors for transducing cells from the central nervous system.

Mingjie Li1, Nada Husic, Ying Lin, B Joy Snider.   

Abstract

Efficient gene delivery in the central nervous system (CNS) is important in studying gene functions, modeling neurological diseases and developing therapeutic approaches. Lentiviral vectors are attractive tools in transduction of neurons and other cell types in CNS as they transduce both dividing and non-dividing cells, support sustained expression of transgenes, and have relatively large packaging capacity and low toxicity. Lentiviral vectors have been successfully used in transducing many neural cell types in vitro and in animals. Great efforts have been made to develop lentiviral vectors with improved biosafety and efficiency for gene delivery. The current third generation replication-defective and self-inactivating (SIN) lentiviral vectors are depicted in Figure 1. The required elements for vector packaging are split into four plasmids. In the lentiviral transfer plasmid, the U3 region in the 5' long terminal repeat (LTR) is replaced with a strong promoter from another virus. This modification allows the transcription of the vector sequence independent of HIV-1 Tat protein that is normally required for HIV gene expression. The packaging signal (Ψ) is essential for encapsidation and the Rev-responsive element (RRE) is required for producing high titer vectors. The central polypurine tract (cPPT) is important for nuclear import of the vector DNA, a feature required for transducing non-dividing cells. In the 3' LTR, the cis-regulatory sequences are completely removed from the U3 region. This deletion is copied to 5' LTR after reverse transcription, resulting in transcriptional inactivation of both LTRs. Plasmid pMDLg/pRRE contains HIV-1 gag/pol genes, which provide structural proteins and reverse transcriptase. pRSV-Rev encodes Rev which binds to the RRE for efficient RNA export from the nucleus. pCMV-G encodes the vesicular stomatitis virus glycoprotein (VSV-G) that replaces HIV-1 Env. VSV-G expands the tropism of the vectors and allows concentration via ultracentrifugation. All the genes encoding the accessory proteins, including Vif, Vpr, Vpu, and Nef are excluded in the packaging system. The production and manipulation of lentiviral vectors should be carried out according to NIH guidelines for research involving recombinant DNA (http://oba.od.nih.gov/oba/rac/Guidelines/NIH_Guidelines.pdf). An approval from individual Institutional Biological and Chemical Safety Committee may be required before using lentiviral vectors. Lentiviral vectors are commonly produced by cotransfection of 293T cells with lentiviral transfer plasmid and the helper plasmids encoding the proteins required for vector packaging. Many lentiviral transfer plasmids and helper plasmids can be obtained from Addgene, a non-profit plasmid repository (http://www.addgene.org/). Some stable packaging cell lines have been developed, but these systems provide less flexibility and their packaging efficiency generally declines over time. Commercially available transfection kits may support high efficiency of transfection, but they can be very expensive for large scale vector preparations. Calcium phosphate precipitation methods provide highly efficient transfection of 293T cells and thus provide a reliable and cost effective approach for lentiviral vector production. In this protocol, we produce lentiviral vectors by cotransfection of 293T cells with four plasmids based on the calcium phosphate precipitation principle, followed by purification and concentration with ultracentrifugation through a 20% sucrose cushion. The vector titers are determined by fluorescence- activated cell sorting (FACS) analysis or by real time qPCR. The production and titration of lentiviral vectors in this protocol can be finished with 9 days. We provide an example of transducing these vectors into murine neocortical cultures containing both neurons and astrocytes. We demonstrate that lentiviral vectors support high efficiency of transduction and cell type-specific gene expression in primary cultured cells from CNS.

Entities:  

Mesh:

Year:  2012        PMID: 22664962      PMCID: PMC3466950          DOI: 10.3791/4031

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  28 in total

1.  Optimal promoter usage for lentiviral vector-mediated transduction of cultured central nervous system cells.

Authors:  Mingjie Li; Nada Husic; Ying Lin; Heather Christensen; Ibrahim Malik; Sally McIver; Christine M LaPash Daniels; David A Harris; Paul T Kotzbauer; Mark P Goldberg; B Joy Snider
Journal:  J Neurosci Methods       Date:  2010-03-27       Impact factor: 2.390

2.  Dual-promoter lentiviral vectors for constitutive and regulated gene expression in neurons.

Authors:  Sergio Gascón; Juan A Paez-Gomez; Margarita Díaz-Guerra; Peter Scheiffele; Francisco G Scholl
Journal:  J Neurosci Methods       Date:  2007-09-29       Impact factor: 2.390

3.  Lentivirus production.

Authors:  Xiaoyin Wang; Michael McManus
Journal:  J Vis Exp       Date:  2009-10-02       Impact factor: 1.355

4.  Neuron-specific gene transfer through retrograde transport of lentiviral vector pseudotyped with a novel type of fusion envelope glycoprotein.

Authors:  Shigeki Kato; Masahito Kuramochi; Kenji Takasumi; Kenta Kobayashi; Ken-ichi Inoue; Daisuke Takahara; Seiji Hitoshi; Kazuhiro Ikenaka; Takashi Shimada; Masahiko Takada; Kazuto Kobayashi
Journal:  Hum Gene Ther       Date:  2011-09-09       Impact factor: 5.695

5.  New protocol for lentiviral vector mass production.

Authors:  María Mercedes Segura; Alain Garnier; Yves Durocher; Sven Ansorge; Amine Kamen
Journal:  Methods Mol Biol       Date:  2010

6.  The human immunodeficiency virus type-1 central DNA flap is a crucial determinant for lentiviral vector nuclear import and gene transduction of human hematopoietic stem cells.

Authors:  A Sirven; F Pflumio; V Zennou; M Titeux; W Vainchenker; L Coulombel; A Dubart-Kupperschmitt; P Charneau
Journal:  Blood       Date:  2000-12-15       Impact factor: 22.113

7.  Regulator of G-protein signaling-10 negatively regulates NF-κB in microglia and neuroprotects dopaminergic neurons in hemiparkinsonian rats.

Authors:  Jae-Kyung Lee; Jaegwon Chung; Fiona E McAlpine; Malú G Tansey
Journal:  J Neurosci       Date:  2011-08-17       Impact factor: 6.167

8.  Efficient gene transduction of neurons by lentivirus with enhanced neuron-specific promoters.

Authors:  H Hioki; H Kameda; H Nakamura; T Okunomiya; K Ohira; K Nakamura; M Kuroda; T Furuta; T Kaneko
Journal:  Gene Ther       Date:  2007-03-15       Impact factor: 5.250

9.  A new-generation stable inducible packaging cell line for lentiviral vectors.

Authors:  D Farson; R Witt; R McGuinness; T Dull; M Kelly; J Song; R Radeke; A Bukovsky; A Consiglio; L Naldini
Journal:  Hum Gene Ther       Date:  2001-05-20       Impact factor: 5.695

10.  Simplified production and concentration of HIV-1-based lentiviral vectors using HYPERFlask vessels and anion exchange membrane chromatography.

Authors:  Robert H Kutner; Sharon Puthli; Michael P Marino; Jakob Reiser
Journal:  BMC Biotechnol       Date:  2009-02-16       Impact factor: 2.563

View more
  15 in total

1.  A tetracycline-regulated cell line produces high-titer lentiviral vectors that specifically target dendritic cells.

Authors:  Paul D Bryson; Chupei Zhang; Chi-Lin Lee; Pin Wang
Journal:  J Vis Exp       Date:  2013-06-19       Impact factor: 1.355

2.  Expression of Exogenous Cytokine in Patient-derived Xenografts via Injection with a Cytokine-transduced Stromal Cell Line.

Authors:  Jacqueline S Coats; Ineavely Baez; Cornelia Stoian; Terry-Ann M Milford; Xiaobing Zhang; Olivia L Francis; Ruijun Su; Kimberly J Payne
Journal:  J Vis Exp       Date:  2017-05-10       Impact factor: 1.355

3.  Live cell imaging of primary rat neonatal cardiomyocytes following adenoviral and lentiviral transduction using confocal spinning disk microscopy.

Authors:  Takashi Sakurai; Anthony Lanahan; Melissa J Woolls; Na Li; Daniela Tirziu; Masahiro Murakami
Journal:  J Vis Exp       Date:  2014-06-24       Impact factor: 1.355

4.  Overexpression of KAI1 inhibits retinoblastoma metastasis in vitro.

Authors:  Hui Yan; Xunda Ji; Jing Li; Lei Zhang; Peiquan Zhao
Journal:  Oncol Lett       Date:  2016-12-16       Impact factor: 2.967

5.  Engineering Artificial Factors to Specifically Manipulate Alternative Splicing in Human Cells.

Authors:  Huan-Huan Wei; Yuanlong Liu; Yang Wang; Qianyun Lu; Xuerong Yang; Jiefu Li; Zefeng Wang
Journal:  J Vis Exp       Date:  2017-04-26       Impact factor: 1.355

6.  Using Caco-2 Cells to Study Lipid Transport by the Intestine.

Authors:  Andromeda M Nauli; Judy D Whittimore
Journal:  J Vis Exp       Date:  2015-08-20       Impact factor: 1.355

7.  Modeling Neuronal Death and Degeneration in Mouse Primary Cerebellar Granule Neurons.

Authors:  Matthew Laaper; Takrima Haque; Ruth S Slack; Arezu Jahani-Asl
Journal:  J Vis Exp       Date:  2017-11-06       Impact factor: 1.355

8.  Heritable and inducible gene knockdown in astrocytes or neurons in vivo by a combined lentiviral and RNAi approach.

Authors:  Fabrice Heitz; Torbjörn Johansson; Karsten Baumgärtel; Rreze Gecaj; Pawel Pelczar; Isabelle M Mansuy
Journal:  Front Cell Neurosci       Date:  2014-03-19       Impact factor: 5.505

9.  Deregulated hedgehog pathway signaling is inhibited by the smoothened antagonist LDE225 (Sonidegib) in chronic phase chronic myeloid leukaemia.

Authors:  David A Irvine; Bin Zhang; Ross Kinstrie; Anuradha Tarafdar; Heather Morrison; Victoria L Campbell; Hothri A Moka; Yinwei Ho; Colin Nixon; Paul W Manley; Helen Wheadon; John R Goodlad; Tessa L Holyoake; Ravi Bhatia; Mhairi Copland
Journal:  Sci Rep       Date:  2016-05-09       Impact factor: 4.379

10.  Interleukin-6 and rs1800796 locus single nucleotide polymorphisms in response to hypoxia/reoxygenation in hepatocytes.

Authors:  Zhaowen Wang; Shaohan Wu; Jianhua Liao; Lin Zhong; Tonghai Xing; Junwei Fan; Zhihai Peng
Journal:  Int J Mol Med       Date:  2016-05-18       Impact factor: 4.101

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.